Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NanoValent Pharmaceutical Partners with Children's Hospital of Los Angeles

Abstract:
Nanovalent Pharmaceuticals of Bozeman, Montana has entered into a collaboration with oncology researchers at Children's Hospital of Los Angeles. The partnership will focus on generating efficacy data in murine models of Ewing's Sarcoma and Acute Lymphoblastic Leukemia utilizing Nanovalent's drug candidates NANO-EW and NANO-ALL.

NanoValent Pharmaceutical Partners with Children's Hospital of Los Angeles

Bozeman, MT | Posted on December 1st, 2007

NANO-EW, NanoValent's lead cancer drug candidate is a transferrin surface targeted nanoparticle loaded with the chemotherapeutic SN38. The Company's primary indication is Ewing's Sarcoma. However, the firm intends to expand development efforts to include non-small cell lung cancer and hepatocellular carcinoma.

NANO-ALL is a transferrin surface targeted nanoparticle delivering siRNA fragments intended to silence gene sequences specific to acute lymphoblastic leukemia.

The Company is developing therapeutics against pediatric and adult cancers using proprietary polymerized liposomal nanoparticle (PLN) drug delivery technology.

####

About Nanovalent Pharmaceuticals
NanoValent Pharmaceuticals, Inc. (NVP) is a Delaware C-corporation commercializing a drug delivery platform that differentiates itself from other particle delivery systems through several key features. NanoValent particles are highly robust, customizable, stable, cheap, and easy to manufacture. The technology is capable of delivering a wide array of drug molecules or drug cocktails using multiple tissue targeting ligands. While other firms have successfully used targeted particles to deliver pharmaceuticals, few competitors have a payload specific custom offering with the flexibility to target using any surface ligand and deliver virtually any drug or biological payload. The platform product and manufacturing protocols are complete and the company has secured patents along with significant grant funding. The Company’s strategy is to develop several internal delivery programs, while leveraging the versatility of the platform technology providing custom drug delivery solutions to academic and private drug development programs. Internal development efforts are focused on vaccines, cancer therapeutics, and RNAi delivery.

Contacts:
James Hamilton MD, MBA
President


Jon Nagy PhD
Lead Scientist


Tim Trich MD, PhD
Chief Medical Officer

Copyright © NanoValent Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

New, old science combine to make faster medical test: Nanoparticles and Faraday rotation allow faster diagnoses January 23rd, 2017

New research helps to meet the challenges of nanotechnology: Research helps to make the most of nanoscale catalytic effects for nanotechnology January 20th, 2017

Chemists Cook up New Nanomaterial and Imaging Method: Nanomaterials can store all kinds of things, including energy, drugs and other cargo January 19th, 2017

'5-D protein fingerprinting' could give insights into Alzheimer's, Parkinson's January 19th, 2017

Announcements

Bruker Announces Acquisition of Nanoindenting Leader Hysitron: Acquisition strengthens Bruker’s leading position in nanoanalysis and nanomechanical materials characterization January 24th, 2017

New low-cost technique converts bulk alloys to oxide nanowires January 24th, 2017

News from Quorum: Experienced electron microscopist, David McCarthy, talks about working with Quorum and his use of their coaters and cryo-SEM preparation instrumentation January 24th, 2017

Tough aqua material for water purification: Decontamination of water with a robust and sustainable membrane assembled from 2 synergistically working components January 24th, 2017

Alliances/Trade associations/Partnerships/Distributorships

GLOBALFOUNDRIES Expands Partner Program to Speed Time-to-Market of FDX™ Solutions: Increased support affirms FDXcelerator™ Program’s vital role in promoting broader deployment of GLOBALFOUNDRIES’ FDX™ portfolio December 15th, 2016

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

Leti and Grenoble Partners Demonstrate World’s 1st Qubit Device Fabricated in CMOS Process: Paper by Leti, Inac and University of Grenoble Alpes Published in Nature Communications November 28th, 2016

Mechanism for sodium storage in 2-D material: Tin selenide is an effective host for storing sodium ions, making it a promising material for sodium ion batteries October 27th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project